

Alaska Medical Assistance DUR Committee Meeting Minutes

Friday, April 16, 2021

Meeting was held Telephonically due to COVID-19. 1:00PM

Drug Utilization Review Committee Attendees

Members Present	Non Members Present
Erin Narus, PharmD (DHSS)	Umang Patel, PharmD (Magellan)
Charles Semling, PharmD (DHSS)	Ryan Ruggles, PharmD, MSHI (Magellan)
Charles Ryan, MD	
Robert Carlson, MD	
Barb Piromalli, DO	
Jonathon Harrison, PharmD	Members Absent
	Dr. Heath McAnally, MD
	Keri McCutcheon, RPh

Call to order at 1:05 PM.

Review of Agenda

Charles Semling went over the Agenda to the committee members.

Review of minutes from November 2020

Charles Semling asked the committee if they had any changes to the minutes. There were none.

Motion to approve Charles Ryan.

Second by Barb Piromalli.

Minutes approved.

Overview of Medicaid Prescription and Cost Trends

Charles Semling went through the detail of the program trend snapshot. Claims were lower year over year, but overall more expensive.

Both PMPM/PUPM trends seem to have evened out over the last few months and there seems to be fewer swings above and below the trend line.

Top 25 drugs and classes have not changed in some time. Rare disease and biologics are largely driving the spend.

Prospective Drug Utilization Review/Clinical Topic Areas

New Prescription Medications (Interim PA List – 6 month review)

Interim PA list was short for this meeting. Charles Semling presented the logic for these medications and conditions that they treat. The committee agreed that the list seemed reasonable.

The committee reviewed a list of drugs that have been on the suspend list for over 400 days and have not seen any use. Charles Semling requested that the committee remove these items from the suspend list since they were not being utilized. There was no concern over the removal of those drugs from the list.

New Prior Authorizations, Quantity Limits, Edits

Imcivree criteria was presented.

There was discussion about the criteria and inadvertently stopping therapy due to small weight change.

Charles Semling assured the committee that the patient doing well on the drug would not be denied coverage.

It was also discussed how rare the disease is, and how normally weight loss drugs aren't covered, but the weight loss is secondary to the treatment of the condition.

Charles Ryan moved to approve.

Second by Barb Piromalli

Esbriet criteria was presented.

It was reviewed by the committee.

Questions regarding the FVC were presented, and the state will double check the language on 7.

Justifications were presented.

Charles Ryan moved to approve with rechecking the questioned line.

Barb Piromalli seconded.

Wakix criteria was presented.

It was reviewed by the committee.

Barb Piromalli moved to approve.

Charles Ryan seconded.

Mytesi criteria was presented.

It was reviewed by the committee.

Charles Ryan moved to approve as written.

Barb Piromalli seconded.

Evkeeza criteria was presented.

It was reviewed by the committee.

Erin Narus asked about the origin of point 3. It was from the package insert.

Charles Ryan moved to approve.

Barb Piromalli seconded.

Conversation occurred regarding "free samples" and if their use should or should not be considered as part of the criteria. The committees feeling was that it should not be considered part of the trial process.

Opioid Report

Charles Semling presented the opioid use tables.

During the past few months, we have had an uptick in December then back down again.

There was some brief discussion about drugs moving in certain directions, and a comment regarding.

Currently the MME max without PA is 200, and the next scheduled reduction is in July.

Charles Semling mentioned a partnership with University of Washington, and TelePain assistance that is free for providers in Alaska.

A question was presented about patients having multiple prescribers, and whether or not it was worth notifying the prescribers of this. Discussion of shared charts could be confounding variables.

ICD-10 Compliance report was presented to the committee. The committee pointed out some nuances in attempting to interpret the data.

ICD-10 Compliance report for Stimulants was presented.

Discussion on how to continue or further utilize the reports ensued, and a suggestion to combine average MME and ICD-10 Compliance reports.

Antipsychotic use for patients <22 years old and lab frequency

Data was presented on lab frequency, and it was noted about how many children were on antipsychotics. The State is currently working on collaborations with other organizations for recommendations for Alaska patients.

Charles Semling presented a notification to prescribers alerting them to the patients that did not have labs.

The committee approved of the intent and the language of the letter.

Safety Reports

Charles Semling presented the FDA safety report regarding Xeljanz. FDA is continuing to monitor for potential heart problems.

FAERS Reports

FAERS Report was presented, and reviewed by the committee. Charles Semling specifically pointed out that PPIs are being reviewed for rhabdomyolysis.

Notice to Pharmacies

Notice that the brand is preferred over generics being sent to pharmacies in order to encourage compliance with the PDL. It was then explained to the committee how and why brand medications may be more cost effective for the state.

Charles Ryan moved to approve.

Barb Piromalli seconded.

Committee approved the sending of the letter.

Post meeting comments

Charles Semling expressed thanks to the committee members for their thoughts and comments in trying to help the community.

End of Public Meeting

Adjournment 2:41 p.m.

Next meeting date September 17th, 2021.